Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Bladder Cancer

  Free Subscription


1 Adv Radiat Oncol
3 Anticancer Res
2 Arch Ital Urol Androl
1 Biochem Biophys Res Commun
1 Bioengineered
1 Biomed Res Int
1 Biomolecules
1 BMC Cancer
1 Cancer Med
1 Cancer Radiother
1 Cell Cycle
1 Cell Death Dis
1 Cell Oncol (Dordr)
1 Clin Cancer Res
3 Environ Toxicol
1 Front Genet
1 Future Oncol
1 Hinyokika Kiyo
1 Hum Pathol
1 Infect Dis Rep
1 Inquiry
1 Int J Med Robot
1 Int J Mol Sci
1 Int J Nanomedicine
1 Int J Radiat Oncol Biol Phys
3 Int Urol Nephrol
1 J Magn Reson Imaging
1 J Med Radiat Sci
1 Metabolomics
2 Mod Pathol
1 Mol Carcinog
1 Nat Commun
1 Pak J Biol Sci
3 Urol Int
7 Urol Oncol
2 Urology
3 World J Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Adv Radiat Oncol

  1. POLINENI P, Ashack L, Kalapurakal J, Morgans A, et al
    Trimodality Treatment for Muscle-Invasive Bladder Cancer: An Institutional Experience.
    Adv Radiat Oncol. 2021;6:100718.
    PubMed         Abstract available

    Anticancer Res

  2. FOSSUM CC, Xiong Y, Magliocco A, Daneshmand S, et al
    Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2021;41:3851-3857.
    PubMed         Abstract available

  3. MUKAE Y, Ito H, Miyata Y, Araki K, et al
    Ceruloplasmin Levels in Cancer Tissues and Urine Are Significant Biomarkers of Pathological Features and Outcome in Bladder Cancer.
    Anticancer Res. 2021;41:3815-3823.
    PubMed         Abstract available

  4. MASILAMANI AP, Fischer A, Schultze-Seemann S, Kuckuck I, et al
    Epidermal Growth Factor Based Targeted Toxin for the Treatment of Bladder Cancer.
    Anticancer Res. 2021;41:3741-3746.
    PubMed         Abstract available

    Arch Ital Urol Androl

  5. MITRAKAS L, Gravas S, Karasavvidou F, Zachos I, et al
    Endothelin-1 indicates unfavorable prognosis in primary high-grade non-muscle-invasive urothelial bladder cancer.
    Arch Ital Urol Androl. 2021;93:143-147.
    PubMed         Abstract available

  6. AKGUL M, Baykan O, Cagman Z, Ozyurek M, et al
    Gas6 expression and Tyrosine kinase Axl Sky receptors: Their relation with tumor stage and grade in patients with bladder cancer.
    Arch Ital Urol Androl. 2021;93:148-152.
    PubMed         Abstract available

    Biochem Biophys Res Commun

  7. ZHANG F, Wu H
    MiR-599 targeting TOP2A inhibits the malignancy of bladder cancer cells.
    Biochem Biophys Res Commun. 2021;570:154-161.
    PubMed         Abstract available


  8. ZHANG F, Wang X, Hu H, Yang Y, et al
    A hypoxia related long non-coding RNA signature could accurately predict survival outcomes in patients with bladder cancer.
    Bioengineered. 2021;12:3802-3823.
    PubMed         Abstract available

    Biomed Res Int

  9. CHE X, Zhan J, Zhao F, Zhong Z, et al
    Oridonin Promotes Apoptosis and Restrains the Viability and Migration of Bladder Cancer by Impeding TRPM7 Expression via the ERK and AKT Signaling Pathways.
    Biomed Res Int. 2021;2021:4340950.
    PubMed         Abstract available


  10. STURARO G, Tasso A, Menilli L, Di Liddo R, et al
    4,6,4'-Trimethylangelicin Photoactivated by Blue Light Might Represent an Interesting Option for Photochemotherapy of Non-Invasive Bladder Carcinoma: An In Vitro Study on T24 Cells.
    Biomolecules. 2021;11.
    PubMed         Abstract available

    BMC Cancer

  11. TANG X, Qian WL, Yan WF, Pang T, et al
    Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study.
    BMC Cancer. 2021;21:823.
    PubMed         Abstract available

    Cancer Med

  12. BALLAS LK, Navarro S, Luo C, Fossum CC, et al
    Disparities in male versus female oncologic outcomes following bladder preservation: A population-based cohort study.
    Cancer Med. 2021;10:3004-3012.
    PubMed         Abstract available

    Cancer Radiother

  13. DETTI B, Sardaro A, Maragna V, Mariotti M, et al
    Radiotherapy is effective in the management of rare penile metastases: Two case reports.
    Cancer Radiother. 2021;25:480-483.
    PubMed         Abstract available

    Cell Cycle

  14. TIAN Y, Gao P, Dai D, Chen L, et al
    Circular RNA circSETD3 hampers cell growth, migration, and stem cell properties in bladder cancer through sponging miR-641 to upregulate PTEN.
    Cell Cycle. 2021 Jul 21:1-14. doi: 10.1080/15384101.2021.1954758.
    PubMed         Abstract available

    Cell Death Dis

  15. YANG C, Mou Z, Wu S, Ou Y, et al
    High-throughput sequencing identified circular RNA circUBE2K mediating RhoA associated bladder cancer phenotype via regulation of miR-516b-5p/ARHGAP5 axis.
    Cell Death Dis. 2021;12:719.
    PubMed         Abstract available

    Cell Oncol (Dordr)

  16. SHAN G, Zhou X, Gu J, Zhou D, et al
    Correction to: Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/beta-catenin pathway and upregulating PTEN.
    Cell Oncol (Dordr). 2021 Jul 20. pii: 10.1007/s13402-021-00615.

    Clin Cancer Res

  17. TEO MY, Rosenberg JE
    NECTIN4 heterogeneity and molecular diversity in bladder cancers: deconstructing the activity of an antibody-drug conjugate.
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1807.
    PubMed         Abstract available

    Environ Toxicol

  18. ZHANG Q, Hao L, Shen Z, Wang F, et al
    MiR-186-5p suppresses cell migration, invasion, and epithelial mesenchymal transition in bladder cancer by targeting RAB27A/B.
    Environ Toxicol. 2021 Jul 22. doi: 10.1002/tox.23331.
    PubMed         Abstract available

  19. KAO CC, Cheng YC, Yang MH, Cha TL, et al
    Demethoxycurcumin induces apoptosis in HER2 overexpressing bladder cancer cells through degradation of HER2 and inhibiting the PI3K/Akt pathway.
    Environ Toxicol. 2021 Jul 22. doi: 10.1002/tox.23332.
    PubMed         Abstract available

  20. CHOU KY, Chen PC, Chang AC, Tsai TF, et al
    Attenuation of chloroquine and hydroxychloroquine on the invasive potential of bladder cancer through targeting matrix metalloproteinase 2 expression.
    Environ Toxicol. 2021 Jul 19. doi: 10.1002/tox.23328.
    PubMed         Abstract available

    Front Genet

  21. WANG Z, Wang X, Wang Y, Tang S, et al
    Transcriptomic Analysis of Gene Networks Regulated by U11 Small Nuclear RNA in Bladder Cancer.
    Front Genet. 2021;12:695597.
    PubMed         Abstract available

    Future Oncol

  22. FERRO M, Lucarelli G, de Cobelli O, Dolce P, et al
    A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy.
    Future Oncol. 2021 Jul 19. doi: 10.2217/fon-2020-1298.
    PubMed         Abstract available

    Hinyokika Kiyo

  23. KOBAYASHI G, Takayanagi A, Shindo T, Hashimoto K, et al
    [A Case of Diagnosed Lynch Syndrome in a Patient with Ureteral Cancer].
    Hinyokika Kiyo. 2021;67:229-232.
    PubMed         Abstract available

    Hum Pathol

  24. GRIGG CM, Livasy C, He J, Hartman A, et al
    Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity.
    Hum Pathol. 2021;107:96-103.
    PubMed         Abstract available

    Infect Dis Rep

  25. BRANCO EA, Duro R, Brito T, Sarmento A, et al
    Granulomatous Hepatitis Following Intra-Vesical Instillation of Bacillus Calmette-Guerin for Treatment of Bladder Cancer.
    Infect Dis Rep. 2021;13:611-618.
    PubMed         Abstract available


  26. BESSA A, Bosco C, Cahill F, Russell B, et al
    Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience.
    Inquiry. 2021;58:469580211030217.
    PubMed         Abstract available

    Int J Med Robot

  27. YANG R, Du Y, Weng X, Chen Z, et al
    Automatic recognition of bladder tumours using deep learning technology and its clinical application.
    Int J Med Robot. 2021;17:e2194.
    PubMed         Abstract available

    Int J Mol Sci

  28. KIM IH, Lee HJ
    Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives.
    Int J Mol Sci. 2021;22.
    PubMed         Abstract available

    Int J Nanomedicine

  29. WEN J, Yang T, Mallouk N, Zhang Y, et al
    Urinary Exosomal CA9 mRNA as a Novel Liquid Biopsy for Molecular Diagnosis of Bladder Cancer.
    Int J Nanomedicine. 2021;16:4805-4811.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  30. BUSZEK SM, Ludmir EB, Grosshans DR, McAleer MF, et al
    Disease Control and Patterns of Failure After Proton Beam Therapy for Rhabdomyosarcoma.
    Int J Radiat Oncol Biol Phys. 2021;109:718-725.
    PubMed         Abstract available

    Int Urol Nephrol

  31. AZEVEDO RM, de Oliveira Carneiro J, da Silva NDF, Athanazio DA, et al
    Bladder venous malformation.
    Int Urol Nephrol. 2021;53:281-282.

  32. WANG Y, Shen W, Yuan X, Akezhouli S, et al
    A perioperative management to reduce rate of urinary tract infection for patient underwent radical cystectomy with ileal conduit diversion.
    Int Urol Nephrol. 2020 Oct 17. pii: 10.1007/s11255-020-02653.
    PubMed         Abstract available

  33. TAKAMATSU K, Matsumoto K, Kikuchi E, Ogihara K, et al
    Can random bladder biopsies be eliminated after bacillus Calmette-Guerin therapy against carcinoma in situ?
    Int Urol Nephrol. 2021;53:465-469.
    PubMed         Abstract available

    J Magn Reson Imaging

  34. LEWIS S, Galsky M
    Editorial for "Preliminary Exploration of the Application of Vesical Imaging-Reporting and Data System (VI-RADS) in Post-Treatment Patients with Bladder Cancer: A Prospective Single-Center Study".
    J Magn Reson Imaging. 2021 Jul 19. doi: 10.1002/jmri.27843.

    J Med Radiat Sci

  35. DOWER K, Ford A, Sandford M, Doherty A, et al
    Retrospective evaluation of planning margins for patients undergoing radical radiation therapy treatment for bladder cancer using volumetric modulated arc therapy and cone beam computed tomography.
    J Med Radiat Sci. 2021 Jul 20. doi: 10.1002.
    PubMed         Abstract available


  36. TU A, Said N, Muddiman DC
    Spatially resolved metabolomic characterization of muscle invasive bladder cancer by mass spectrometry imaging.
    Metabolomics. 2021;17:70.
    PubMed         Abstract available

    Mod Pathol

  37. CHAN E, Garg K, Stohr BA
    Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer.
    Mod Pathol. 2020 Apr 20. pii: 10.1038/s41379-020-0543.
    PubMed         Abstract available

  38. ZHU MMT, Burugu S, Gao D, Yu J, et al
    Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types.
    Mod Pathol. 2020 Apr 29. pii: 10.1038/s41379-020-0550.
    PubMed         Abstract available

    Mol Carcinog

  39. TSAI CW, Chang WS, Xu Y, Huang M, et al
    Associations of genetically predicted circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with bladder cancer risk.
    Mol Carcinog. 2021 Jul 22. doi: 10.1002/mc.23334.
    PubMed         Abstract available

    Nat Commun

  40. BANCHEREAU R, Leng N, Zill O, Sokol E, et al
    Molecular determinants of response to PD-L1 blockade across tumor types.
    Nat Commun. 2021;12:3969.
    PubMed         Abstract available

    Pak J Biol Sci

  41. JAMAL A, Shahid I, Naveed Shahid M, Saleh Alshmemri M, et al
    Human Papillomavirus, MicroRNA and their Role in Cervical Cancer Progression, Diagnosis and Treatment Response: A Comprehensive Review.
    Pak J Biol Sci. 2020;23:977-988.
    PubMed         Abstract available

    Urol Int

  42. YANG C, Lv Z, Li Y
    Reduction of Bladder Volume after BCG Immunotherapy.
    Urol Int. 2021;105.
    PubMed         Abstract available

  43. IZOL V, Deger M, Ozden E, Bolat D, et al
    The Effect of Diagnostic Ureterorenoscopy on Intravesical Recurrence in Patients Undergoing Nephroureterectomy for Primary Upper Tract Urinary Carcinoma.
    Urol Int. 2021;105.
    PubMed         Abstract available

  44. KAYNAR M, Celik ZE, Altintas E, Batur AF, et al
    Comparison of Two Different Bipolar Energy Resources in Transurethral Resection of Bladder Tumors.
    Urol Int. 2021;105.
    PubMed         Abstract available

    Urol Oncol

  45. POSADA CALDERON L, Al Hussein Al Awamlh B, Shoag J, Patel N, et al
    The role of surgical experience in patient selection, surgical quality, and outcomes in robot-assisted radical cystectomy.
    Urol Oncol. 2021;39:6-12.
    PubMed         Abstract available

  46. KARDOUST PARIZI M, Margulis V, Compe Rat E, Shariat SF, et al
    The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis.
    Urol Oncol. 2021;39:15-33.
    PubMed         Abstract available

  47. LAUKHTINA E, Pradere B, Mori K, Schuettfort VM, et al
    Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review.
    Urol Oncol. 2021;39:180-190.
    PubMed         Abstract available

    Relentlessly make yourself obsolete: Robot-assisted radical cystectomy, the emerging standard of care.
    Urol Oncol. 2021;39:13-14.

  49. SMITH AB, Samuel CA, McCabe SD, Deal A, et al
    Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients.
    Urol Oncol. 2021;39:77.
    PubMed         Abstract available

  50. DRAKAKI A, Pantuck A, Mhatre SK, Dhillon PK, et al
    "Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma.
    Urol Oncol. 2021;39:76.
    PubMed         Abstract available

  51. AMANO N, Matsumoto K, Shimizu Y, Nakamura M, et al
    High HNRNPA3 expression is associated with lymph node metastasis and poor prognosis in patients treated with radical cystectomy.
    Urol Oncol. 2021;39:196.
    PubMed         Abstract available


  52. RICHTER LA, Egan J, Alagha EC, Handa VL, et al
    Vaginal Complications after Radical Cystectomy for Bladder Cancer: A Systematic Review.
    Urology. 2021 Jul 17. pii: S0090-4295(21)00656.
    PubMed         Abstract available

  53. HERR H, Vertosick EA, Dalbagni G, Cha EK, et al
    Prospective Phase II Study to Evaluate Response to Two Induction Courses (12 intravesical instillations) of BCG Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer.
    Urology. 2021 Jul 15. pii: S0090-4295(21)00642.
    PubMed         Abstract available

    World J Urol

  54. ZHOU Z, Gao Z, Wu J, Cui Y, et al
    Safety and efficacy of bipolar versus monopolar transurethral resection of bladder tumor: a systematic review and meta-analysis.
    World J Urol. 2021;39:2249-2250.

  55. BEANO H, He J, Hensel C, Worrilow W, et al
    Safety of decreasing ureteral stent duration following radical cystectomy.
    World J Urol. 2021;39:473-479.
    PubMed         Abstract available

  56. SHARMA G, Sharma AP, Mavuduru RS, Bora GS, et al
    Safety and efficacy of bipolar versus monopolar transurethral resection of bladder tumor: a systematic review and meta-analysis.
    World J Urol. 2021;39:377-387.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.